Eli Lilly to invest USD 5.3bn in obesity drug production

The US-based pharmaceutical firm has recently experienced shortages of its bestseller weight-loss drug Zepbound. 
Photo: Brendan Mcdermid
Photo: Brendan Mcdermid
by marketwire

US Novo Nordisk competitor Eli Lilly will spend USD 5.3bn on increasing production of a key ingredient in its weight loss and diabetes treatments after their explosive popularity led to shortages.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading